Primary thrombocythemia can be vaccinated and has no adverse effects. 1. Primary thrombocythemia is a chronic myeloproliferative disorder, which clinically manifests as thrombocytosis and megakaryocyte proliferation, and is treated mainly to prevent bleeding and thrombosis. Most cases progress slowly, and a few patients may transform into other types of myeloproliferative tumors. Patients with cardiovascular risk factors should be treated by controlling blood pressure levels and blood glucose levels, and by active smoking cessation. Hydroxyurea can be given as maintenance therapy as the first line of cytostatic therapy. Small-dose aspirin can also be given for antiplatelet therapy. 2. Contraindications to the administration of the new coronavirus vaccine are generally the acute onset of chronic disease, the presence of a history of immune system disorders in the patient or the presence of severe allergic reactions to previous vaccinations. Patients with primary thrombocythemia can receive the vaccine if there are no such contraindications. Clinically, it is recommended that patients with primary thrombocythemia consult the hematology department of a regular hospital, and consult a specialist for vaccination.